论文部分内容阅读
目的:观察消瘤汤治疗进展期胃癌术后患者的临床疗效及对血清血管内皮生长因子(vascular endothelial growth factor,VEGF)含量的影响。方法:选取河北省中医院2010年1月至2012年1月进展期胃癌术后患者共80例。随机分为对照组和观察组,对照组予5-FU+CF+L-OHP化疗,观察组在对照组治疗的基础上加用消瘤汤治疗。对比两组患者治疗前和治疗4个周期后的临床症状积分、肿瘤标志物水平及VEGF-B、VEGF-C、VEGF-D血清表达水平和骨髓抑制情况。结果:治疗后观察组腹痛腹胀、食欲减退、恶心呕吐、消瘦乏力及腹泻等症状积分显著低于对照组(P<0.05),血清VEGF-B、VEGF-C、VEGF-D含量显著低于对照组(P<0.05),术后1、3年生存率显著高于对照组(P<0.01)。结论:消瘤汤治疗进展期胃癌术后患者可有效改善其临床症状,降低血清VEGF蛋白含量,提高患者术后1、3年生存率。
Objective: To observe the clinical efficacy of Xiaoluotang in the treatment of advanced gastric cancer patients and its effect on the content of serum vascular endothelial growth factor (VEGF). Methods: A total of 80 cases of advanced gastric cancer patients from January 2010 to January 2012 in Hebei Provincial Hospital of Traditional Chinese Medicine were selected. Randomly divided into control group and observation group, the control group was given 5-FU + CF + L-OHP chemotherapy. The observation group was treated with Xiaoyu Tang on the basis of the control group. Clinical symptom score, tumor marker level, serum levels of VEGF-B, VEGF-C, VEGF-D and myelosuppression were compared between the two groups before treatment and after 4 cycles of treatment. Results: After treatment, the scores of abdominal pain, abdominal distension, loss of appetite, nausea and vomiting, weight loss and diarrhea in observation group were significantly lower than those in control group (P <0.05), and the levels of VEGF-B, VEGF-C and VEGF- Group (P <0.05). The postoperative 1 and 3 year survival rates were significantly higher than those in the control group (P <0.01). Conclusion: Xiaoluotang in the treatment of patients with advanced gastric cancer can effectively improve the clinical symptoms, reduce the serum VEGF protein content and improve the survival rate of patients after 1, 3 years.